Open an account

Atea Pharmaceuticals

AVIR · NASDAQ

$4.47+$0.075 (+1.71%)TodayMarket closed ·
Prev close $4.39

About AVIR

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 55 full-time employees. The company went IPO on 2020-10-30. The firm is focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. The firm has built a proprietary nucleos(t)ide prodrug platform to develop product candidates to treat single-stranded ribonucleic acid (ssRNA) viruses, which are a prevalent cause of serious viral diseases. The Company’s lead program and focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an investigational, potent, small-molecule inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A), an essential protein for HCV replication. Bemnifosbuvir is an investigational, orally administered guanosine nucleotide double prodrug which targets the HCV non-structural protein 5B (NS5B) RNA-dependent RNA polymerase and inhibits HCV replication.

Employees
55
Headquarters
Boston, Massachusetts
Listed
Oct 30, 2020
Sector
Health Care
Industry
Pharmaceuticals
Website
ateapharma.com

AVIR key statistics

Market cap
358.11M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
296.81K
Volume
288.01K
Open price
$4.40
High today
$4.58
Low today
$4.32
52 Week high
$6.45
52 Week low
$2.87

Atea Pharmaceuticals (AVIR) at a glance

As of Oct 20, 2026, Atea Pharmaceuticals (AVIR) shares are priced at $4.47, giving the company a market cap of 358.11M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $4.32 and $4.58. The current price is 3.5% above the day's low and 2.5% below its high.

Volume so far is 288.01K shares, in line with the average of 296.81K shares a day.

Over the past year Atea Pharmaceuticals has ranged from $2.87 to $6.45, and now sits 45% of the way up that range.

Atea Pharmaceuticals met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.41 per share against an estimate of -$0.5712.

The average analyst price target is $8.67, 94.2% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 2 analyst ratings say Buy
  • Buy50.0%
  • Hold50.0%
  • Sell0.0%
Price target · 4 analystsAvg $8.67
Low
$7.07
Now
$4.47
High
$10.50

AVIR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 16.1% on average.

  1. Q3 FY24: reported -$0.37 per share against an estimate of -$0.5049
  2. Q4 FY24: reported -$0.40 per share against an estimate of -$0.3774
  3. Q1 FY25: reported -$0.40 per share against an estimate of -$0.4182
  4. Q2 FY25: reported -$0.44 per share against an estimate of -$0.4233
  5. Q3 FY25: reported -$0.53 per share against an estimate of -$0.4488
  6. Q4 FY25: reported -$0.57 per share against an estimate of -$0.5406
  7. Q1 FY26: reported -$0.57 per share against an estimate of -$0.6018
  8. Q2 FY26: reported -$0.41 per share against an estimate of -$0.5712

AVIR news

  • Vandana Singh

    Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial

  • Press releaseBusiness Wire

    ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO

  • Insights Ahead: Atea Pharmaceuticals's Quarterly Earnings

  • Press releaseBusiness Wire

    ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman

  • Atea Pharmaceuticals Earnings Preview

  • Press releaseBusiness Wire

    The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

  • Press releaseBusiness Wire

    Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process

  • Vandana Singh

    After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study

Similar companies

Companies in the same industry as Atea Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.